REFERENCES
- Bozza, S., Montagnoli, C., Gaziano, R., Rossi, G., Nkwanyuo, G., Bellocchio, S., Romani, L. (2004). Dendritic cell-based vaccination against opportunistic fungi. Vaccine 22: 857–864.
- Capilla, J., Clemons, K. V., Liu, M., Levine, H. B., Stevens, D. A. (2009). Saccharomyces cerevisiae as a vaccine against coccidioidomycosis. Vaccine 27:3662–3668.
- Cardenas-Freytag, L., Cheng, E., Mayeux, P., Domer, J. E., Clements, J. D. (1999). Effectiveness of a vaccine composed of heat-killed Candida albicans and a novel mucosal adjuvant, LT(R192G), against systemic candidiasis. Infect. Immun, 67: 826–833.
- Cassone, A. (2008). Fungal vaccines: real progress from real challenges. Lancet Infect. Dis. 8:114–124.
- Clemons, K. V., Stevens, D. A. (2001). Efficacy of the partricin derivative SPA-S-753 against systemic murine candidosis. J. Antimicrob. Chemother. 47:183–186.
- Conti, H. R., Shen, F., Nayyar, N., Stocum, E., Sun, J. N., Lindemann, M. J., Ho, A. W., Hai, J. H., Yu, J. J., Jung, J. W., Filler, S. G., Masso-Welch, P., Edgerton, M., Gaffen, S. L. (2009). Th17 cells and IL-17 receptor signaling are essential for mucosal host defense against oral candidiasis. J. Exp. Med. 206:299–311.
- Cutler, J. E., Deepe, G. S., Jr., Klein, B. S. (2007). Advances in combating fungal diseases: vaccines on the threshold. Nat. Rev. Microbiol. 5:13–28.
- Diaz-Arevalo, D., Hong, T. B., Ito, J. I., Clemons, K. V., Stevens, D. A., Kalkum, M. (2011). Quantitative and comparative proteomic analyses of pathogenic fungi. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, American Society for Microbiology: Abstr. M-310.
- DiMiceli, L., Pool, V., Kelso, J. M., Shadomy, S. V., Iskander, J. (2006). Vaccination of yeast sensitive individuals: review of safety data in the US vaccine adverse event reporting system (VAERS). Vaccine 24:703–707.
- Ferwerda, G., Netea, M. G., Joosten, L. A., van der Meer, J. W., Romani, L., Kullberg, B. J. (2010). The role of Toll-like receptors and C-type lectins for vaccination against Candida albicans. Vaccine 28:614–622.
- Fidel, P. L., Jr., Ginsburg, K. A., Cutright, J. L., Wolf, N. A., Leaman, D., Dunlap, K., Sobel, J. D. (1997). Vaginal-associated immunity in women with recurrent vulvovaginal candidiasis: evidence for vaginal Th1-type responses following intravaginal challenge with Candida antigen. J. Infect. Dis. 176:728–739.
- Franzusoff, A., Duke, R. C., King, T. H., Lu, Y., Rodell, T. C. (2005). Yeasts encoding tumour antigens in cancer immunotherapy. Expert Opin Biol Ther 5:565–575.
- Hajjeh, R. A., Sofair, A. N., Harrison, L. H., Lyon, G. M., Arthington-Skaggs, B. A., Mirza, S. A., Phelan, M., Morgan, J., Lee-Yang, W., Ciblak, M. A., Benjamin, L. E., Sanza, L. T., Huie, S., Yeo, S. F., Brandt, M. E., Warnock, D. W. (2004). Incidence of bloodstream infections due to Candida species and in vitro susceptibilities of isolates collected from 1998 to 2000 in a population-based active surveillance program. J. Clin. Microbiol. 42:1519–1527.
- Han, Y., Ulrich, M. A., Cutler, J. E. (1999). Candida albicans mannan extract-protein conjugates induce a protective immune response against experimental candidiasis. J. Infect. Dis. 179:1477–1484.
- Hanson, L. H., Perlman, A. M., Clemons, K. V., Stevens, D. A. (1991). Synergy between cilofungin and amphotericin B in a murine model of candidiasis. Antimicrob. Agents Chemother. 35:1334–1337.
- Hoeprich, P. D., Finn, P. D. (1972). Obfuscation of the activity of antifungal antimicrobics by culture media. J. Infect. Dis. 126:353–361.
- Huang, W., Na, L., Fidel, P. L., Schwarzenberger, P. (2004). Requirement of interleukin-17A for systemic anti-Candida albicans host defense in mice. J. Infect. Dis. 190: 624–631.
- La Sala, A., Urbani, F., Torosantucci, A., Cassone, A., Ausiello, C. M. (1996). Mannoproteins from Candida albicans elicit a Th-type-1 cytokine profile in human Candida specific long-term T cell cultures. J. Biol. Regul. Homeost. Agents 10:8–12.
- Lachin, J. M. (1999). Worst-rank score analysis with informatively missing observations in clinical trials. Control Clin. Trials 20:408–422.
- Lin, L., Ibrahim, A. S., Xu, X., Farber, J. M., Avanesian, V., Baquir, B., Fu, Y., French, S. W., Edwards, J. E., Jr., Spellberg, B. (2009). Th1-Th17 cells mediate protective adaptive immunity against Staphylococcus aureus and Candida albicans infection in mice. PLoS Pathog 5:e1000703.
- Liu, M., Capilla, J., Johansen, M. E, Alvarado, D., Martinez, M., Chen, V. Clemons, K. V., Stevens, D. A. (2011a). Saccharomyces as a vaccine against systemic aspergillosis. J. Med. Microbiol. 60:1423–1432.
- Liu, M., Clemons, K. V., Bigos, M., Medovarska, I., Brummer, E., Stevens, D. A. (2011b). Immune responses induced by heat killed Saccharomyces cerevisiae: A vaccine against fungal infection. Vaccine 29:1745–1753.
- Liu, M., Clemons, K., Bystricky, S., Stevens, D. (2010). Glycans and conjugates as vaccines against coccidioidomycosis. 50th Interscience Conference on Antimicrobial Agents and Chemotherapy, Boston, MA, Am. Soc. Microbiol.: Abstr G1-1657
- Liu, M., Machova, E., Nescakova, Z., Medovarska, I., Clemons, K.V., Martinez, M., Chen, V., Bystricky, S., Stevens, D.A. Vaccination with mannan protects mice against systemic aspergillosis. Med. Mycol., in press.
- Lu, Y., Bellgrau, D., Dwyer-Nield, L. D., Malkinson, A. M., Duke, R. C., Rodell, T. C., Franzusoff, A. (2004). Mutation-selective tumor remission with Ras-targeted, whole yeast-based immunotherapy. Cancer Res. 64:5084–5088.
- Majumder, T., Liu, M., Chen, V., Martinez, M., Alvarado, D., Clemons, K. V., Stevens, D. A. (2011). Killed Saccharomyces cerevisiae protects against lethal challenge with Cryptococcus grubii. 51st Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, IL, American Society for Microbiology: Abstr. G1-769.
- Morrison, C. J., Stevens, D. A. (1990). Comparative effects of cilofungin and amphotericin B on experimental murine candidiasis. Antimicrob. Agents Chemother. 34: 746–750.
- Munson, S., Parker, J., King, T., Lu, Y., Kelley, V., Guo, Z., Borges, V., Franzusoff, A. (2008). Coupling innate and adaptive immunity with yeast-based cancer immunotherapy. In: Orentas, R., Hodge, J. W., and Johnson, B. D., editors. Cancer Vaccines and Tumor Immunity. John Wiley & Sons: Hoboken, NJ, pp. 131–149.
- Raska, M., Belakova, J., Horynova, M., Krupka, M., Novotny, J., Sebestova, M., Weigl, E. (2008). Systemic and mucosal immunization with Candida albicans hsp90 elicits hsp90-specific humoral response in vaginal mucosa which is further enhanced during experimental vaginal candidiasis. Med. Mycol. 46:411–420.
- Shih, W. (2002). Problems in dealing with missing data and informative censoring in clinical trials. Curr. Control Trials Cardiovasc. Med. 3:4.
- Spellberg, B. J., Ibrahim, A. S., Avanesian, V., Fu, Y., Myers, C., Phan, Q. T., Filler, S. G., Yeaman, M. R., Edwards, J. E., Jr. (2006). Efficacy of the anti-Candida rAls3p-N or rAls1p-N vaccines against disseminated and mucosal candidiasis. J. Infect. Dis. 194:256–260.
- Stevens, D. A., Clemons, K. V., Liu, M. (2010). Developing a vaccine against aspergillosis. Med. Mycol. 49(Suppl 1): S170–S176.
- Torosantucci, A., Bromuro, C., Chiani, P., De Bernardis, F., Berti, F., Galli, C., Norelli, F., Bellucci, C., Polonelli, L., Costantino, P., Rappuoli, R., Cassone, A. (2005). A novel glyco-conjugate vaccine against fungal pathogens. J. Exp. Med. 202:597–606.
- Warnock, D. W. (2007). Trends in the epidemiology of invasive fungal infections. Nippon Ishinkin Gakkai Zasshi 48:1–12.
- Wu, X., Lipinski, T., Carrel, F. R., Bailey, J. J., Bundle, D. R. (2007). Synthesis and immunochemical studies on a Candida albicans cluster glycoconjugate vaccine. Org. Biomol. Chem. 5:3477–3485.
- Xin, H., Dziadek, S., Bundle, D. R., Cutler, J. E. (2008). Synthetic glycopeptide vaccines combining beta-mannan and peptide epitopes induce protection against candidiasis. Proc. Natl. Acad. Sci. USA 105:13526–13531.